

High-Sensitivity Troponin and the Diagnosis of NSTEMI in Hospitalized Medical Patients

Gidi Stein, Danny Alon, Roman Korenfeld, Shmuel Fuchs

Department of Internal Medicine "B", Beilinson Hospital, Rabin Medical Center

IHS Annual Meeting, April 22-23, 2013, Jerusalem Israel



Conflict of interest





Background

■ The 3rd universal definition of MI

 "...detection of a rise and/or fall of cardiac troponin with at least one value above the 99th percentile upper reference limit and with a strong pre-test likelihood"

ACCF 2012 expert consensus document

"…an elevated troponin is a finding that represents the likely occurrence of myocardial necrosis and does not in and of itself provide any indication of the etiology"



Background

- Troponin levels were obtained in 25% of ER allcomers (McFalls et al. Am J Med. 2011) and it's utilization is steadily growing at 6.9% annually
- Several studies examine relative and absolute changes in hsTn levels in the distinction of ischemic vs. non-ischemic conditions
 - Diff>0.009ug/1 Mueller et al. Clinical Chemistry, 2012
 - Diff>30% Agewall et al. EHJ, 2011
 - Diff>50% (20% if b/l is û) Thygesenet al. EHJ, 2012



Background

Since 2010, high-sensitivity troponin assays are being used in Rabin Medical Center

 Data is lacking on the prevalence and kinetics of elevated high-sensitivity troponin levels in hospitalized complex patients



Study outline

- All patients hospitalized to 8 medical wards in Rabin Medical Center, Israel throughout 2011
- 18,830 admissions of 13,029 patients were included in the study
- 5,696 admissions of 4,615 patients with at least one high-sensitivity Troponin (hsTn) measurement (30%)
- 10,021 hsTn measurements were included



Baseline Characteristics

Age (average±stdev)	71.5 <u>+</u> 15
Male gender (%)	53.5
Acute diagnosis (%)	
Non specific chest pain	24.1
Acute coronary syndrome	2.1
Myocardial infarction	4
Heart failure	23
Anemia	21.9
COPD exacerbation	17.2
Acute renal failure	6.3
Pulmonary emboli	2
Sepsis	2




Baseline Characteristics

Patient Comorbidities (%)	
Ischemic heart disease	41.7
Heart failure	24.3
Post CVA	14.1
Diabetes	35.7
Chronic renal failure	19.4
Atrial Fibrillation	25.2
COPD	16.9
Malignancy	13.7


HsTn Measurements per Admission

RABIN MEDICAL CENTER BEILINSON • HASHARON






HsTn levels Distribution






Absolute and Relative Change by hsTn Levels






HsTn levels & % Change by Age & Renal Function







HsTn Levels and Kinetics per Acute Dx







RABIN MEDICAL CENTER BEILINSON • HASHARON




%-change does not contribute to precision

HsTn threshold of 0.1 ug/l includes 60% of ACS/MI and excludes 88% of non-ACS/MI admissions




$HsTn \ge 0.1 ug/1$



HsTn and 30-day Mortality

RABIN MEDICAL CENTER BEILINSON • HASHARON





Multivariate Analysis for 30-day Mortality

Parameter	OR (95% CI)	р
Age	1.03 (1.02, 1.04)	<0.0001
Creatinin	1.17 (1.1, 1.26)	<0.0001
Chest Pain	0.18 (0.1, 0.32)	<0.0001
Sepsis	11.17 (7.27, 17.17)	<0.0001
ARF	1.66 (1.18, 2.33)	0.004
MI/ACS	0.46 (0.27, 0.79)	0.005
hsTn>0.013	4.58 (2.8, 7.49)	<0.0001



Conclusions I

- Elevated hsTn as well as its dynamic changes are common among hospitalized patients in Internal Medicine wards across multiple medical conditions
- Age and chronic renal failure are associated with elevated hsTn levels
- In 94% of the patients who had elevated hsTn the cause was not ACS/MI



Conclusions II

- High max hsTn levels but not magnitude of dynamic changes were more frequent among patients with ACS
- HsTn > 99% percentile is and independent predictor for early mortality
- These results underline the complexity of the utilization of hsTn in diagnosis of NSTEMI in medical patients with atypical symptoms